These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34320390)

  • 1. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
    J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
    Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S
    Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.
    Marot S; Malet I; Leducq V; Abdi B; Teyssou E; Soulie C; Wirden M; Rodriguez C; Fourati S; Pawlotsky JM; Boutolleau D; Burrel S; Calvez V; Marcelin AG; Jary A
    Clin Infect Dis; 2022 Mar; 74(4):707-710. PubMed ID: 34050731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV.
    Gidari A; Bastianelli S; Pierucci S; Busti C; Sabbatini S; Schiaroli E; Benedetti S; Gamboni G; Lanzi A; Francisci D
    Curr HIV Res; 2022; 20(4):296-300. PubMed ID: 35909272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
    Hein S; Herrlein ML; Mhedhbi I; Bender D; Haberger V; Benz N; Eisert J; Stingl J; Dreher M; Oberle D; Schulze J; Mache C; Budt M; Hildt C; Wolff T; Hildt E
    Allergy; 2022 Jul; 77(7):2080-2089. PubMed ID: 34820854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.
    Lopera TJ; Chvatal-Medina M; Flórez-Álvarez L; Zapata-Cardona MI; Taborda NA; Rugeles MT; Hernandez JC
    Front Immunol; 2022; 13():879036. PubMed ID: 35585980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum.
    Zhu Y; Yang X; Xun J; Liu J; Wen Q; Lin Y; Shen X; Chen J; Yuan S; Zhao X; Wang J; Pan H; Yang J; Liang Z; Liang Y; Lin Q; Liang H; Li M; Liu J; Shen Y; Zhang X; Wang P; Lu D; Yin C; Xu J; Jiang S; Lu H; Zhu H
    Virol Sin; 2022 Dec; 37(6):831-841. PubMed ID: 36309305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination.
    Trabace L; Pace L; Morgese MG; Santo IB; Galante D; Schiavone S; Cipolletta D; Rosa AM; Reveglia P; Parisi A; Tucci P; Pepe G; Sacco R; Foschino Barbaro MP; Corso G; Fasanella A
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
    Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
    Front Immunol; 2021; 12():743422. PubMed ID: 34659239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
    Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
    medRxiv; 2021 Jul; ():. PubMed ID: 34373860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
    J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
    Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.